Merck’s CETP inhibitor lowers risk of cardiac events
admin 28th June 2017 Uncategorised 0Merck & Co’s CETP inhibitor anacetrapib has hit its key target in the late-stage REVEAL study, showing a significant reduction in major coronary events in at-risk patients already on a cholesterol-lowering regimen.
More: Merck’s CETP inhibitor lowers risk of cardiac events
Source: News